Neoadjuvant and Adjuvant Chemotherapy Treatment Patterns Among Older Triple-negative and HER2-positive Breast Cancer Patients with Comorbidities

被引：0
|
作者：
Tamirisa, Nina [1 ]
Dong, Wenli [1 ]
Shen, Yu [1 ]
Shaitelman, Simona [1 ]
Babiera, Gildy [1 ]
Bedrosian, Isabelle [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
ANNALS OF SURGICAL ONCOLOGY | 2023年 / 30卷 / SUPPL 2期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1387856
引用
收藏
页码：S315 / S316
页数：2
相关论文
共 50 条
  • [41] Risk Factors for Ipsilateral Breast Tumor Recurrence in Triple-Negative or HER2-Positive Breast Cancer Patients Who Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy
    Makoto Ishitobi
    Naoko Matsuda
    Mizuho Tazo
    Sayuka Nakayama
    Ryu Tokui
    Tomoko Ogawa
    Atsushi Yoshida
    Yasuyuki Kojima
    Takashi Kuwayama
    Takahiro Nakayama
    Hideko Yamauchi
    Seigo Nakamura
    Koichiro Tsugawa
    Naoki Hayashi
    Annals of Surgical Oncology, 2021, 28 : 2545 - 2552
  • [42] Tumour residue after neoadjuvant chemotherapy for triple-negative or Her 2+breast cancer
    El Karroumi, Mohammed
    Benhessou, Mustapha
    Ennachit, Simohammed
    Bencherifi, Younes
    Fadil, Kaoutar
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A142 - A142
  • [43] A brief review of treatment options for neoadjuvant chemotherapy in patients with triple-negative breast cancer
    Tiwari, Akash
    INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2020, 41 (02) : 247 - 249
  • [44] PROGNOSTIC SIGNIFICANCE OF ANDROGEN RECEPTOR EXPRESSION IN HER2-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCER
    Kucukzeybek, Betul Bolat
    Bayoglu, Ibrahim V.
    Kucukzeybek, Yuksel
    Yildiz, Yasar
    Oflazoglu, Utku
    Atahan, Murat K.
    Taskaynatan, Halil
    Alacacioglu, Ahmet
    Yigit, Seyran
    Tarhan, Mustafa O.
    POLISH JOURNAL OF PATHOLOGY, 2018, 69 (02) : 157 - 168
  • [45] Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
    Stevic, Ines
    Mueller, Volkmar
    Weber, Karsten
    Fasching, Peter A.
    Karn, Thomas
    Marme, Frederic
    Schem, Christian
    Stickeler, Elmar
    Denkert, Carsten
    van Mackelenbergh, Marion
    Salat, Christoph
    Schneeweiss, Andreas
    Pantel, Klaus
    Loibl, Sibylle
    Untch, Michael
    Schwarzenbach, Heidi
    BMC MEDICINE, 2018, 16
  • [46] Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
    Schlam, Ilana
    Dower, Joshua
    Lynce, Filipa
    CURRENT ONCOLOGY REPORTS, 2024, 26 (04) : 336 - 345
  • [47] TLE1 protein expression in HER2-positive and triple-negative breast cancer
    Lee, H. J.
    Oh, M-H
    Lee, J-H
    Cho, H. D.
    Jang, S-H
    Jung, H. Y.
    Kim, K-J
    CANCER RESEARCH, 2016, 76
  • [48] Addressing Residual Disease in HER2-Positive and Triple-Negative Breast Cancer: What Is Next?
    Ilana Schlam
    Joshua Dower
    Filipa Lynce
    Current Oncology Reports, 2024, 26 : 336 - 345
  • [49] Adjuvant chemotherapy in T1a/bN0 HER2-positive or triple-negative breast cancers: Application and outcomes
    Migdady, Yazan
    Sakr, Bachir J.
    Sikov, William M.
    Olszewski, Adam J.
    BREAST, 2013, 22 (05): : 793 - 798
  • [50] Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial
    Ines Stevic
    Volkmar Müller
    Karsten Weber
    Peter A. Fasching
    Thomas Karn
    Frederic Marmé
    Christian Schem
    Elmar Stickeler
    Carsten Denkert
    Marion van Mackelenbergh
    Christoph Salat
    Andreas Schneeweiss
    Klaus Pantel
    Sibylle Loibl
    Michael Untch
    Heidi Schwarzenbach
    BMC Medicine, 16
12345